Johnson & Johnson (NYSE:JNJ) said today that closed the $2.1 billion sale of its LifeScan blood glucose monitoring subsidiary to private equity player Platinum Equity.
The sale is part of the New Brunswick, N.J.-based healthcare conglomerate’s move to get out of the device end of the diabetes business. Early last year J&J announced a strategic review of the LifeScan, Animas and Calibra Medical diabetes businesses, later opting to outright shutter the Animas insulin pump subsidiary.
Get the full story at our sister site, Drug Delivery Business News.
The post Johnson & Johnson closes $2B LifeScan sale appeared first on MassDevice.
from MassDevice https://ift.tt/2DNLLvx
Cap comentari:
Publica un comentari a l'entrada